Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, today announced the successful completion its financing round with its current syndicate of investors. The round was led by VRD GmbH (Heidelberg) with S-Refit AG (Regensburg, Germany), Wolf Biotech GmbH (Starnberg, Germany), Bayern Kapital (Landshut, Germany) and High-Tech Gründerfonds GmbH (Bonn, Germany) participating.
Proceeds from this round of financing will be used to further strengthen the commercialization and expansion of existing diagnostic kits as well as of the portfolio of novel T cell based research tools. “Management and investors are very much looking forward to a further fruitful collaboration and successful company development” Dr. Robert Phelps, Lophius’ Chief Executive Officer said.
Proceeds from this round of financing will be used to further strengthen the commercialization and expansion of existing diagnostic kits as well as of the portfolio of novel T cell based research tools. “Management and investors are very much looking forward to a further fruitful collaboration and successful company development” Dr. Robert Phelps, Lophius’ Chief Executive Officer said.
